SYNBIOTIC SE Expands Portfolio Amid Integration Challenges

SYNBIOTIC SE has made strategic advancements by integrating new companies into its portfolio, despite halting the integration of CannaCare Health due to financial reporting delays. Analyst Christian Sandherr maintains a "BUY" rating for SYNBIOTIC, with a target price of EUR 12.40 over 12 months.

WEECO Pharma, a major holding within SYNBIOTIC, has surpassed sales expectations following increased demand for medical cannabis. By October, the company reported € 6.75 million in sales, exceeding the FY24 target of € 6 million. Projections now estimate revenues to reach € 8.2 million, making it SYNBIOTIC's largest revenue source.

SYNBIOTIC's acquisition of stakes in GOC NEXUS GmbH and greensby suggests a focus on diversifying its cannabis-related interests. GOC NEXUS specializes in cold plasma decontamination technology, while greensby connects various cannabis industry stakeholders and plans to expand its offerings.